InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（3 笔）
内部人交易记录
董事已披露买入
0
已披露卖出
3
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Aker Christopher Ray, Vice-Président Senior et Conseiller Juridique Général. Insider active across 2 companies, notably Regulus Therapeutics Inc.. Cumulatively, 6 filings have been published. Breakdown: 0 buy · 3 sells. Total volume traded: €54k. History available since 17 May 2021. The latest transaction was filed on 13 January 2025 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Aker Christopher Ray
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
60,796 股Common StockSEC:0000950170-25-091019:0
38,547 股@ US$1.263233.5% 占其流量Common StockSEC:0000950170-25-005882:0
66,625 股@ US$1.3661.9% 占其流量Common StockSEC:0000950170-25-004270:0
5,468 股@ US$1.19064.2% 占其流量Common StockSEC:0001209191-24-001874:0
11,250 股0Common StockSEC:0001209191-24-001771:0
860 股@ US$0.890.4% 占其流量Common StockSEC:0001209191-21-033296:0
6 条申报中的 6 条
About Aker Christopher Ray
Christopher Ray Aker is the Senior Vice President and General Counsel at Regulus Therapeutics Inc. He is responsible for managing the company's legal affairs, including regulatory compliance and intellectual property protection. His expertise in business law and regulation is essential to support Regulus Therapeutics' mission.
